MediWound is a biopharmaceutical company that develops, manufactures, and commercializes novel, cost effective, non-surgical bio-therapeutic solutions for tissue repair and regeneration. Our strategy leverages our enzymatic technology platform, focused on next-generation bioactive therapies for burn care, wound care and tissue repair.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
2022 total revenues of $26.5 million FDA approval of NexoBrid ® in December 2022 ; U.S. commercial availability expected in the second quarter of 2023 EscharEx ® Phase III protocol design is under review by the FDA; study to be initiated in the second half of 2023 C ash position of $66 million ,
YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms.